Nektar Therapeutics (NKTR) Files Form 4 Insider Selling : John Nicholson Sells 856 Shares

Nektar Therapeutics (NKTR): John Nicholson , SVP & Chief Financial Officer of Nektar Therapeutics sold 856 shares on May 17, 2016. The Insider selling transaction was reported by the company on May 18, 2016 to the Securities and Exchange Commission. The shares were sold at $13.58 per share for a total value of $11,624.48 , the company said in a SEC Form 4 Filing.

Other Insider transactions have been reported by the company according to SEC Form 4, on May 18, 2016, Stephen K Doberstein (SVP & Chief Scientific Officer) sold 339 shares at $13.58 per share price.On May 18, 2016, Maninder Hora (SVP Pharma Dev & Mfg Ops) sold 835 shares at $13.58 per share price.Also, On May 18, 2016, Gil M Labrucherie (SVP & General Counsel) sold 836 shares at $13.58 per share price.On May 18, 2016, Jillian B. Thomsen (SVP & Chief Accounting Officer) sold 724 shares at $13.58 per share price.

Shares of Nektar Therapeutics (NKTR) ended Thursday, May 19, 2016 session in red amid volatile trading. The shares closed down -0.26 points or -1.90% at $13.39 with 6,39,429 shares getting traded. Post opening the session at $13.57, the shares hit an intraday low of $13.17 and an intraday high of $13.78 and the price vacillated in this range throughout the day. The company has a market cap of $1,824,562 M and the number of outstanding shares has been calculated to be 1,36,26,30,00,000 shares. The 52-week high of Nektar Therapeutics is $17.55 and the 52-week low is $9.16.

Nektar Therapeutics Money Flow Index Chart

Nektar Therapeutics is a clinical-stage biopharmaceutical company. The Company is engaged in the development of a pipeline of drug candidates that utilize its PEGylation and advanced polymer conjugate technology platforms which are designed to enable the development of new molecular entities that target known mechanisms of action. The Company’s pipeline is comprised of drug candidates for therapeutic areas including oncology pain anti-infectives and immunology. The Company’s research and development activities involve small molecule drugs peptides and other potential biologic drug candidates. Its drug candidates are designed to improve the pharmacokinetics pharmacodynamics half-life bioavailability metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient. Its polymer chemistry platform is being used to create specialized therapeutics including small molecule oral and parenteral drugs proteins peptides and antibody fragments.

Leave a Reply

Nektar Therapeutics - Is it time to Sell?

Top Brokerage Firms are advising their investors on Nektar Therapeutics. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.